Galapagos, a clinical stage biotechnology company in the United States, is a joint venture between Crucell and Tibotec. With an efficient business model and strategic partnerships in place, Galapagos has risen to become one of the top big biotech companies. The company’s partnering activity are reviewed in the article.
The following figure shows the level of Galapagos partnering deal announcements since 2009. Although partnering frequency in the last couple of years has fallen mildly, the company still seeks for partners in the oncology, musculoskeletal and immuno-inflammatory disease areas.
Figure 1: Galapagos partnering deals 2009-2014
Figure 1: Galapagos partnering deals 2009-2014
Source: Current Agreements, 2014
Analysis of the partnering deals shows a strong emphasis on partnerships in musculoskeletal and immunology diseases. The company predominantly seeks partners in the rheumatoid arthritis, osteoarthritis and immune-inflammatory disorders
The following table provides an overview of the partnering deals announced by Galapagos based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Report: Partnering Agreements with Galapagos 2009-2014
Figure 2: Galapagos partnering deals by therapy area 2009-2014
Figure 2: Galapagos partnering deals by therapy area 2009-2014
Source: Current Agreements, 2014
Further analysis of these deals shows that Galapagos has a preference for collaborative R&D, licensing and option deals, similar to many other top pharmaceutical or big biotech companies. Such partnering deals provide the right for Galapagos to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.
The following table provides an overview of the partnering deals announced by Galapagos based on deal type disclosed.
Figure 3: Galapagos partnering deals by deal type 2009-2014
Source: Current Agreements, 2014
Galapagos is a clinical stage biotechnology company and embarks on conducting safety and efficacy trials of its candidate drugs. So the company partners for compounds at the discovery and preclinical stage to conduct clinical trials and develop the compounds.
The following table provides an overview of the partnering deals announced by Galapagos based on stage of development at signature.
Figure 4: Galapagos partnering by stage of development 2009-2014
Figure 4: Galapagos partnering by stage of development 2009-2014
Source: Current Agreements, 2014
Galapagos has signed over 20 partnering, collaborative R&D and licensing deals since 2009 with companies like Abbvie, GSK, Roche and Servier. A good example of a high value deal entered into by Galapagos is the collaborative R&D, licensing and option agreement announced in July 2010 with Servier. The strategic alliance was initiated to develop new therapies in osteoarthritis.
The following provides a summary of the top deals by headline value entered into by Galapagos.
Figure 5: Top Galapagos partnering deals by headline value 2009-2014
Figure 5: Top Galapagos partnering deals by headline value 2009-2014
Source: Current Agreements, 2014
Our report provides more detailed insight into the details of each deal.
See: Partnering Agreements with Galapagos 2009-2014
Galapagos partnering at Current Agreements
View all partnering deals for Galapagos: 2014 | 2013 | 2012 | 2011 | 2010 | 2009
Full details on each deal can be found at CurrentAgreements (subscription required)
More
Summary profile data for Galapagos
Partnering interests for Galapagos
Available reports from Current Partnering
Report: Partnering Agreements with Galapagos 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Galapagos
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Read: more on Galapagos company profile, recent partnering, M&A and financing news and articles
Related
Report: Finding Biopharma Licensing and Collaboration Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter
